Antibacterial resistance is one of the biggest threats to health and economy worldwide since it dramatically reduces the probability to effectively treat infections, increasing the morbidity and mortality associated with bacterial diseases. ESKAPE pathogens are responsible for the majority of nosocomial infections and are capable of “escaping” the biocidal action of antimicrobial agents. The term “ESKAPE” encompasses six such pathogens with growing multidrug resistance and virulence: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. Multidrug-resistant (MDR) bacteria and extensively drug-resistant (XDR) bacteria are types of drug-resistant organisms that are resistant to almost all, or all approved, antimicrobial agents. Keeping this in mind, there is an urgent need to design and engineer new antibiotics and antibiotic classes.
This Research Topic welcomes the submission of all article types, with a preference for Original Research, Reviews, and Perspectives that give novel therapeutic alternatives to face multidrug-resistant and extensively drug-resistant bacteria through genetic engineering, synthetic biology, immune therapy, phage therapy, peptide-based therapeutics, and combinatorial treatments.
We also welcome contributions that focus on the a) design and characterization of novel antibacterial agents, including nanoparticles, nanomaterials, nanobiocomposites, etc; b) new antibacterial materials and coatings; c) ecofriendly synthesis methods for nanobiocomposites, and d) antibiotic development for the treatment of MDR and XDR ESKAPE pathogens.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Antibacterial resistance is one of the biggest threats to health and economy worldwide since it dramatically reduces the probability to effectively treat infections, increasing the morbidity and mortality associated with bacterial diseases. ESKAPE pathogens are responsible for the majority of nosocomial infections and are capable of “escaping” the biocidal action of antimicrobial agents. The term “ESKAPE” encompasses six such pathogens with growing multidrug resistance and virulence: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. Multidrug-resistant (MDR) bacteria and extensively drug-resistant (XDR) bacteria are types of drug-resistant organisms that are resistant to almost all, or all approved, antimicrobial agents. Keeping this in mind, there is an urgent need to design and engineer new antibiotics and antibiotic classes.
This Research Topic welcomes the submission of all article types, with a preference for Original Research, Reviews, and Perspectives that give novel therapeutic alternatives to face multidrug-resistant and extensively drug-resistant bacteria through genetic engineering, synthetic biology, immune therapy, phage therapy, peptide-based therapeutics, and combinatorial treatments.
We also welcome contributions that focus on the a) design and characterization of novel antibacterial agents, including nanoparticles, nanomaterials, nanobiocomposites, etc; b) new antibacterial materials and coatings; c) ecofriendly synthesis methods for nanobiocomposites, and d) antibiotic development for the treatment of MDR and XDR ESKAPE pathogens.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.